PRO-AMOXI CLAV 125 MG
CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG · DIN 02536498 · PRO DOC LIMITEE
Health Canada status: MARKETED
What is PRO-AMOXI CLAV?
PRO-AMOXI CLAV 125 MG contains CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02536498, held by PRO DOC LIMITEE, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 10-Jul-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PRO-AMOXI CLAV used for?
Treatment of Sinusitis, Otitis Media, Lower Respiratory Tract Infections, Skin and Soft Tissue Infections, and Urinary Tract Infections caused by susceptible beta-lactamase producing strains.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02536498 |
|---|---|
| Brand name | PRO-AMOXI CLAV |
| Generic / active ingredient | CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 125 MG AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 500 MG |
| Manufacturer | PRO DOC LIMITEE |
| Strength | 125 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 10-Jul-2023 |
How is it administered?
Adults: 500/125 mg q12h or 250/125 mg q8h (mild-mod); 875/125 mg q12h or 500/125 mg q8h (severe). Take at start of a meal to minimize GI intolerance. Do not substitute two 250mg for one 500mg tablet.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 header present but content truncated), though typically 15-30°C for tablets.
How is it supplied?
HDPE bottles of 100 tablets.
Contraindications
History of hypersensitivity to beta-lactams (penicillins, cephalosporins); suspected/confirmed infectious mononucleosis; previous history of amoxicillin/clavulanate-associated hepatic dysfunction.
Warnings and precautions
Serious/fatal hypersensitivity (anaphylaxis) and SCAR; Clostridium difficile-associated disease (CDAD); potential hepatic toxicity/jaundice; superinfections; Kounis syndrome.
Is AMOXICILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR. 28 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AMOXI CLAV | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510634 |
| AG-AMOXI CLAV | 875 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510642 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495910 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 1000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495929 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 2000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495937 |
| AMOXICILLIN/CLAV | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536021 |
| AMOXICILLIN/CLAV | 875 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536048 |
| APO-AMOXI CLAV | 125 MG | TABLET | APOTEX INC | MARKETED | DIN 02243350 |
| APO-AMOXI CLAV | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02243351 |
| APO-AMOXI CLAV | 875 MG | TABLET | APOTEX INC | MARKETED | DIN 02245623 |
Who else supplies AMOXICILLIN AND BETA-LACTAMASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR appears in 3391 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.